



**12 August 2022**

**OMEGA DIAGNOSTICS GROUP PLC**  
(“Omega” or the “Company” or the “Group”)

**Change of preliminary results date and investor presentation  
and update to CD4 sale**

Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition products, provides the following updates regarding the preliminary results for the year ended 31 March 2022, the investor presentation and the completion of sale of its CD4 Business, which was announced on the 3 August 2022.

**Preliminary results and investor presentation update**

The Company’s auditors have requested further time to complete their work ahead of the release of the Company’s preliminary results for the year ended 31 March 2022. The delay is due to a combination of the Company finalising the accounting adjustments in respect to the recent CD4 sale and the subsequent impact on completion of required audit procedures. Consequently, there will be delay to the release of the results, which will now be issued on Thursday 1 September 2022.

The investor presentation relating to the preliminary results which is to be held via the Investor Meet Company platform will now take place on Thursday 1 September 2022 at 4:30pm BST. The presentation is open to all existing and potential shareholders. Investors can sign up to Investor Meet Company for free and add to meet Omega Diagnostics Group plc via:

<https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor>

The Company’s Annual General Meeting date remains unchanged and will be held on 5 October 2022 at 1 Exchange Crescent, Conference Square, Edinburgh EH3 8UL at 11:00am.

**Update on CD4 sale proceeds**

Following the finalisation of the CD4 inventory valuation as at 31 July 2022, there has been an upward revision to the estimated sale proceeds from the originally stated aggregate cash consideration of up to £6.1m, before costs, to up to £6.3m. This results in an increase in the upfront cash payment due to the Company from £1,100,000 to £1,315,000, of which £463,000 has already been received. The balance is due to be received within the next 10 business days.

**Contacts:**

**Omega Diagnostics Group PLC**

Jag Grewal, Chief Executive Officer

Chris Lea, Chief Financial Officer

[www.omegadx.com](http://www.omegadx.com)

via Walbrook PR

**finnCap Ltd**

Geoff Nash/Edward Whiley/George Dollemore (Corporate Finance)

Alice Lane/ Harriet Ward (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Lianne Applegarth

Sam Allen

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)

Mob: 07584 391 303

Mob: 07502 558 258

**About Omega Diagnostics Group PLC**

Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 70 countries and is now focused on the health and nutrition sector.

[www.omegadx.com](http://www.omegadx.com)